GlaxoSmithKline (NYSE: GSK) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.
Insider and Institutional Ownership
9.8% of GlaxoSmithKline shares are held by institutional investors. Comparatively, 49.8% of Marinus Pharmaceuticals shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by insiders. Comparatively, 6.4% of Marinus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares GlaxoSmithKline and Marinus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
GlaxoSmithKline has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than GlaxoSmithKline, indicating that it is currently the more affordable of the two stocks.
This table compares GlaxoSmithKline and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
GlaxoSmithKline has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for GlaxoSmithKline and Marinus Pharmaceuticals, as reported by MarketBeat.com.
||Strong Buy Ratings
GlaxoSmithKline currently has a consensus price target of $38.33, suggesting a potential upside of 4.05%. Marinus Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 91.55%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than GlaxoSmithKline.
GlaxoSmithKline pays an annual dividend of $2.04 per share and has a dividend yield of 5.5%. Marinus Pharmaceuticals does not pay a dividend. GlaxoSmithKline pays out 159.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
GlaxoSmithKline beats Marinus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.